• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Effect of immunomodulatory therapies in patients with pandemic influenza a (h1n1) 2009 complicated by pneumonia

tetano

Editor, Senior Moderator
J Infect. 2011 Feb 2. [Epub ahead of print]
Effect of immunomodulatory therapies in patients with pandemic influenza a (h1n1) 2009 complicated by pneumonia.

Viasus D, Pa?o-Pardo JR, Cordero E, Campins A, L?pez-Medrano F, Villoslada A, Fari?as MC, Moreno A, Rodr?guez-Ba?o J, Oteo JA, Mart?nez-Montauti J, Torre-Cisneros J, Segura F, Carratal? J.

Department of Infectious Diseases, Hospital Universitari de Bellvitge - IDIBELL, University of Barcelona, Barcelona. Feixa Llarga s/n. Postal code 08907.
Abstract

OBJECTIVE: To determine the effect of immunomodulatory therapies on the development of severe disease in hospitalized adults with laboratory-confirmed pandemic influenza A (H1N1) 2009 complicated by pneumonia.

METHODS: Observational, prospective cohort study at thirteen tertiary hospitals in Spain. The use of corticosteroids, macrolides and statins was recorded. The outcome of interest was severe disease, defined as the composite of intensive care unit admission or death after the first day of hospitalization.

RESULTS: Of the 197 patients with pandemic influenza A (H1N1) 2009 complicated by pneumonia, 68 (34.5%) received some anti-inflammatory therapy since hospital admission (corticosteroids in 37, macrolides in 31 and statins in 12). Severe disease occurred in 29 (14.7%) patients. After adjustment for confounding factors, immunomodulatory therapies as a group were not associated with a lower risk for developing severe disease (odds ratio [OR] 0.64; 95% confidence interval [CI] 0.22-1.86). In a further a priori analysis, corticosteroids, macrolides and statins were included in a multivariate model. None of these therapies was found to be associated with a lower risk for developing severe disease.

CONCLUSIONS: Immunomodulatory therapies use since hospital admission did not prevent the development of severe disease in adults with pandemic influenza A (H1N1) 2009 complicated by pneumonia.
Copyright ? 2011. Published by Elsevier Ltd.

PMID: 21295604 [PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/21295604
 
Back
Top Bottom